Original news and analysis on international IP policy
In light of the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
A research group announced in March that it has designed the first minimal synthetic bacterial cell. Rapid advances in science seem to be leaving the international normative process lagging behind. Current international instruments are seeking to understand how this new technology will impact their regulatory efforts, while civil society raises high concerns.
The World Health Organization has released a report on the role of intellectual property in local production of medicines in developing countries. According to the report, the way countries design their intellectual property system is key in the development of local innovation and production. However, health outcomes will depend on the accessibility and affordability of good-quality essential medicines.
Biotherapeutic medicines, engineered by living organisms, have opened a promising path to treat major diseases. Near copies of these medicines, called biosimilars, are slowly coming to market, as the originator products become free of intellectual property rights or data protection.
However, some regulatory issues are left to be addressed, in particular in developing countries, according to the pharmaceutical industry and the World Health Organization. For patients, information on those products and their affordability are key, said a patient group representative.
Public health advocates, academics, patients, governments and others this week presented further ideas to the United Nations Secretary-General’s High-Level Panel on Access to Medicines on ways to break the longstanding pattern of expensive medical products around the world as a way to pay for research and development.
Speakers from Asian civil society provided recommendations to the public hearing of the United Nations Secretary General’s High-Level Panel on Access to Medicines held yesterday. They underlined the unaffordability of medicines in their countries, the inefficiency of current mechanisms such as voluntary licensing, and the pressure applied by pharmaceutical companies and the United States and Europe to prevent the use of compulsory licences. One speaker warned against the expert advice given by the World Intellectual Property Organization to least-developed countries, while others pointed to stringent intellectual property measures in free-trade agreements.
The World Intellectual Property Organization has released data on disputes between trademark owners and third parties who are registering new domain names with the original brand name. Disputes are on the rise and the proportion relating to new generic top-level domain names is growing, it found. Fashion and banking are the prominent areas for disputes.
Today in Johannesburg, South Africa, the second of two public dialogues was held by the United Nations Secretary General’s High-Level Panel on Access to Medicines, drawing another packed room and many ideas, experiences and suggestions for solutions.
China, Japan and South Korea are among the top five countries filing international patent applications at the World Intellectual Property Organization, while the United States continues to lead in patent and trademark applications. Far behind, developing countries seem to be having a hard time catching up.
This year will be the last in office for United Nations Secretary General Ban Ki-moon. A number of Eastern European candidates are being proposed by their governments to be the next secretary general. The UN Framework Convention on Climate Change, as well as the UN Environment Programme are expected to have a new head by summer. Meanwhile, chairs are actively revolving in law offices.
An initiative of the United Nations secretary general yesterday gathered what could be described as an assembly of many of the world’s best thinkers and practitioners on public health and intellectual property rights. Industry, activists, academics, international organisations, and possibly some governments poured out their views for nearly seven hours – at times coming to tears and tension – shepherded by an astute moderator, as they responded to the call to take a longstanding debate on medicines access and high prices to a breakthrough.
Today, Médecins Sans Frontières (MSF, Doctors Without Borders) filed a patent opposition against Pfizer’s vaccine for pneumonia in India.